Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Arnon P. Kater; Sanne H. Tonino; Marjolein Spiering; Martine E. D. Chamuleau; Roberto Liu; Adeboye Henry Adewoye; Jie Gao; Lyndah Dreiling; Yan Xin; Jeanette K. Doorduijn; Marie José Kersten

doi:10.1038/s41408-018-0055-x

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Arnon P. Kater
, Sanne H. Tonino
, Marjolein Spiering
, Martine E. D. Chamuleau
, Roberto Liu
, Adeboye Henry Adewoye
, Jie Gao
, Lyndah Dreiling
, Yan Xin
, Jeanette K. Doorduijn
, Marie José Kersten

Academic Medical Centre, University of Amsterdam
Gilead Sciences, Inc.
Erasmus MC Cancer Institute

Research output: Contribution to journal › Article › Academic › peer-review

11 Downloads (Pure)

Original language	English
Article number	16
Pages (from-to)	16
Journal	Blood cancer journal
Volume	8
Issue number	2
DOIs	https://doi.org/10.1038/s41408-018-0055-x
Publication status	Published - 2018

Access to Document

10.1038/s41408-018-0055-x

Final-results-of-a-phase-1b-study-of-the-safety-and-efficacy-of-the-pi3k-inhibitor-acalisib-gs-9820-in-relapsedrefra.pdfFinal published version, 286 KBLicence: Taverne

Cite this

Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K., & Kersten, M. J. (2018). Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood cancer journal, 8(2), 16. Article 16. https://doi.org/10.1038/s41408-018-0055-x

@article{93c4ffb773804dee9cd1bcf0b4653e5f,

title = "Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies",

author = "Kater, \{Arnon P.\} and Tonino, \{Sanne H.\} and Marjolein Spiering and Chamuleau, \{Martine E. D.\} and Roberto Liu and Adewoye, \{Adeboye Henry\} and Jie Gao and Lyndah Dreiling and Yan Xin and Doorduijn, \{Jeanette K.\} and Kersten, \{Marie Jos{\'e}\}",

year = "2018",

doi = "10.1038/s41408-018-0055-x",

language = "English",

volume = "8",

pages = "16",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "2",

}

Kater, AP , Tonino, SH , Spiering, M , Chamuleau, MED, Liu, R, Adewoye, AH, Gao, J, Dreiling, L, Xin, Y, Doorduijn, JK & Kersten, MJ 2018, 'Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies', Blood cancer journal, vol. 8, no. 2, 16, pp. 16. https://doi.org/10.1038/s41408-018-0055-x

TY - JOUR

T1 - Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

AU - Kater, Arnon P.

AU - Tonino, Sanne H.

AU - Spiering, Marjolein

AU - Chamuleau, Martine E. D.

AU - Liu, Roberto

AU - Adewoye, Adeboye Henry

AU - Gao, Jie

AU - Dreiling, Lyndah

AU - Xin, Yan

AU - Doorduijn, Jeanette K.

AU - Kersten, Marie José

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/pages/publications/85042012706

UR - https://www.ncbi.nlm.nih.gov/pubmed/29434192

U2 - 10.1038/s41408-018-0055-x

DO - 10.1038/s41408-018-0055-x

M3 - Article

C2 - 29434192

SN - 2044-5385

VL - 8

SP - 16

JO - Blood cancer journal

JF - Blood cancer journal

IS - 2

M1 - 16

ER -

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Access to Document

Other files and links

Cite this